Naturally occurring genotype 2b/1a hepatitis C virus in the United States

Virology Journal

Volumn 8, Issue , 2011, Pages

  Bhattacharya, Dipankar ^a   Accola, Molly A ^b   Ansari, Israr H ^a   Striker, Rob ^a,c   Rehrauer, William M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c W S Middleton Memorial Veteran's Association Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; PRIMER DNA;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; PROTEIN CLEAVAGE; UNITED STATES; VIRUS RECOMBINANT; CASE REPORT; CHEMISTRY; DNA FLANKING REGION; GENETIC REASSORTMENT; GENETIC RECOMBINATION; GENETICS; HEPATITIS C; ISOLATION AND PURIFICATION; METHODOLOGY; MIXED INFECTION; MOLECULAR GENETICS; MOLECULAR TYPING; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS GENOME;

HEPATITIS C VIRUS;

3' FLANKING REGION; 5' FLANKING REGION; BASE SEQUENCE; COINFECTION; DNA PRIMERS; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; PHYLOGENY; POLYMERASE CHAIN REACTION; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; UNITED STATES;

EID: 80053442905     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-458     Document Type: Article

References (35)

1. The global burden of hepatitis C. Lavanchy D, Liver Int 2009 1 29 Suppl 74 81
2. Nomenclature and numbering of the hepatitis C virus. Kuiken C, Simmonds P, Methods Mol Biol 2009 510 33 53 10.1007/978-1-59745-394-3-4 19009252
3. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A, Hepatology 2005 42 4 962 973 10.1002/hep.20819 16149085 (Pubitemid 41401136)
4. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Seeff LB, Hoofnagle JH, Hepatology 2002 36 5 Suppl 1 1 2 12407571
5. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. Ramirez S, Perez-del-Pulgar S, Carrion JA, Coto-Llerena M, Mensa L, Dragun J, Garcia-Valdecasas JC, Navasa M, Forns X, J Gen Virol 2010 91 Pt 5 1183 1188 20089799
6. Use of the MagNA Pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. Cook L, Ng KW, Bagabag A, Corey L, Jerome KR, J Clin Microbiol 2004 42 4130 4136 10.1128/JCM.42.9.4130-4136.2004 15365000 (Pubitemid 39296134)
7. Primer sequence modification enhances hepatitis C virus genotype coverage. Tang YM, Sefers SE, Li H, J Clin Microbiol 2005 43 3576 3577 10.1128/JCM.43.7.3576-3577.2005 16000512 (Pubitemid 40981400)
8. Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. Laperche S, Lunel F, Izopet J, Alain S, Deny P, Duverlie G, Gaudy C, Pawlotsky JM, Plantier JC, Pozetto B, Thibault V, Tosetti F, Lefrere JJ, J Clin Microbiol 2005 43 733 739 10.1128/JCM.43.2.733-739.2005 15695672 (Pubitemid 40256027)
9. The Los Alamos hepatitis C sequence database. Kuiken C, Yusim K, Boykin L, Richardson R, Bioinformatics 2005 21 3 379 384 10.1093/bioinformatics/bth485 15377502 (Pubitemid 40246609)
10. Multiple sequence alignment with the Clustal series of programs. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD, Nucleic Acids Res 2003 31 13 3497 3500 10.1093/nar/gkg500 12824352 (Pubitemid 37442184)
11. euHCVdb: the European hepatitis C virus database. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trepo C, Penin F, Deleage G, Nucleic Acids Res 2007 35 Database 363 6
12. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O, Nucleic Acids Res 2008 36 Web Server 465 9
13. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC, J Virol 1999 73 1 152 160 9847317 (Pubitemid 28565356)
14. Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. Kalinina O, Norder H, Magnius LO, J Gen Virol 2004 85 Pt 7 1853 1857 15218169 (Pubitemid 39023263)
15. Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. Chen Z, Weck KE, J Clin Microbiol 2002 40 9 3127 3134 10.1128/JCM.40.9.3127-3134.2002 12202542 (Pubitemid 34977418)
16. Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5' untranslated region (UTR) fails to classify subtypes. Hraber PT, Fischer W, Bruno WJ, Leitner T, Kuiken C, Virol J 2006 3 103 10.1186/1743-422X-3-103 17169155 (Pubitemid 46091621)
17. Evidence for separation of HCV subtype 1a into two distinct clades. Pickett BE, Striker R, Lefkowitz EJ, J Viral Hepat 2010 18 9 608 618 20565573
18. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S, Hepatology 2007 46 3 631 639 10.1002/hep.21781 17680654 (Pubitemid 47436107)
19. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, N Engl J Med 1998 339 21 1485 1492 10.1056/NEJM199811193392101 9819446 (Pubitemid 28543496)
20. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, Lancet 1998 352 9138 1426 1432 10.1016/S0140-6736(98)07124-4 9807989 (Pubitemid 28510876)
21. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J, Hepatology 2000 31 1 211 218 10.1002/hep.510310131 10613748 (Pubitemid 30033709)
22. 2010 College of American of Pathologists Hepatitis Viral Load Proficiency (HVC-L) Survey.
23. Natural intragenotypic and intergenotypic HCV recombinants are rare in southwest China even among patients with multiple exposures. Zhou Y, Wang X, Hong G, Tan Z, Zhu Y, Lan L, Mao Q, J Clin Virol 2010 49 4 272 276 10.1016/j.jcv.2010.08.007 20850377
24. Evidence of recombination in intrapatient populations of hepatitis C virus. Sentandreu V, Jimenez-Hernandez N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, Ortega E, Moya A, Gonzalez-Candelas F, PLoS One 2008 3 9 3239 10.1371/journal.pone.0003239 18800167
25. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. Yamamura J, Ichimura H, J Med Virol 2006 78 1423 1428 10.1002/jmv.20714 16998890 (Pubitemid 44533870)
26. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. Kalinina O, Norder H, Mukomolov S, Magnius LO, J Virol 2002 76 8 4034 4043 10.1128/JVI.76.8.4034-4043.2002 11907242 (Pubitemid 34250567)
27. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form 2b6w. Lee YM, Lin HJ, Chen YJ, Lee CM, Wang SF, Chang KY, Chen TL, Liu HF, Chen YM, J Med Virol 2009 82 57 68
28. New natural intergenotypic (2/5) recombinant of hepatitis C virus. Legrand-Abravanel F, Claudinon J, Nicot F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Pasquier C, Izopet J, J Virol 2007 81 8 4357 4362 10.1128/JVI.02639-06 17267503 (Pubitemid 46586931)
29. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD, Haagmans BL, J Virol 2006 80 15 7569 7577 10.1128/JVI.00312-06 16840336 (Pubitemid 44092578)
30. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Moreau I, Hegarty S, Levis J, Sheehy P, Crosbie O, Kenny-Walsh E, Fanning LJ, Virol J 2006 3 95 10.1186/1743-422X-3-95 17107614 (Pubitemid 44800362)
31. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimagi L, Magnius LO, J Med Virol 2007 79 4 374 382 10.1002/jmv.20828 17311333 (Pubitemid 46355436)
32. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1 2k/1b. Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M, J Infect Dis 2008 198 10 1448 1456 10.1086/592757 18928375
33. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C, N Engl J Med 1996 334 2 77 81 10.1056/NEJM199601113340203 8531962 (Pubitemid 26017933)
34. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB, Nature 2009 461 7262 399 401 10.1038/nature08309 19684573
35. Telaprevir for previously treated chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, N Engl J Med 2010 362 14 1292 1303 10.1056/NEJMoa0908014 20375406